The LCAT gene polymorphism has been proven to increase the risk of dyslipidemia and coronary atherosclerotic heart disease by decreasing the plasma high density lipoprotein cholesterol (HDL-C) levels in humans [45]. This evidence concerns the gene LCAT and metabolic syndrome.